Serum BAFF and APRIL levels in patients with PBC

Kiyoshi Migita, Bibigul Ilyassova, Elena F. Kovzel, Alexander Nersesov, Seigo Abiru, Yumi Maeda, Atsumasa Komori, Masahiro Ito, Koji Yano, Hiroshi Yatsuhashi, Shinji Shimoda, Hiromi Ishibashi, Minoru Nakamura

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

B-cell-activating factor belonging to the TNF family (BAFF) and a proliferation-inducing ligand (APRIL) are known to be involved in the occurrence of autoimmune diseases. We assessed serum levels of these cytokines in PBC patients. Serum BAFF levels were significantly higher in PBC patients than in healthy controls (1253.9 ± 741.4 vs. 722.8 ± 199.2 pg/ml; p < 0.0001) and HCV-infected patients (1253.9 ± 741.4 vs. 871.0 ± 251.1 pg/ml; p = 0.015). Whereas changes in serum APRIL levels were not significant among these groups, there was a significant correlation between BAFF and AST (R = 0.278, p = 0.003) or total bilirubin (R = 0.363, p = 0.0006) in PBC patients. Furthermore, serum BAFF levels were elevated in PBC patients with advanced interface hepatitis. Our data indicate that serum levels of BAFF and APRIL are differentially regulated and serum BAFF levels are significantly elevated in PBC patients. These findings suggest that BAFF may serve as a modulator of the clinical and/or serological manifestation in PBC patients.

Original languageEnglish
Pages (from-to)217-225
Number of pages9
JournalClinical Immunology
Volume134
Issue number2
DOIs
Publication statusPublished - Feb 1 2010

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

Migita, K., Ilyassova, B., Kovzel, E. F., Nersesov, A., Abiru, S., Maeda, Y., ... Nakamura, M. (2010). Serum BAFF and APRIL levels in patients with PBC. Clinical Immunology, 134(2), 217-225. https://doi.org/10.1016/j.clim.2009.09.007